New Delhi, 8th September 2025: Akums Drugs & Pharmaceuticals Ltd., one of India’s leading contract development and manufacturing organizations (CDMOs), has received EAEU GMP certification for its dedicated hormonal manufacturing facility. This milestone enables Akums to supply oral hormonal therapies across the Eurasian Economic Union (EAEU), including Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan.
The certification affirms Akums’ compliance with stringent international standards for pharmaceutical manufacturing and opens doors to regulated market exports in a region with a combined population of over 180 million. The facility is equipped to produce a wide range of oral hormonal formulations, including contraceptives and hormone replacement therapies (HRT), which are in growing demand across Eurasia.
“This certification is a strategic leap forward,” said Mr. Sandeep Jain, Director at Akums. “It reflects our commitment to quality, regulatory excellence, and global market readiness. With this approval, we’re positioned to serve new geographies while continuing to deliver trusted therapies that improve lives.”
The EAEU GMP certification strengthens Akums’ global CDMO credentials and aligns with its broader vision of expanding access to high-quality, affordable medicines. The hormonal plant designed to meet Schedule M and international compliance norms – will support both contract manufacturing and direct supply partnerships with pharmaceutical companies across the Eurasian bloc.
Akums continues to build on its reputation for innovation, scale, and reliability, with a portfolio spanning multiple therapeutic categories and a client base that includes top domestic and international brands.
